2024 SABCS Highlights

 

Many Dana-Farber clinician scientists are participating in the 2024 San Antonio Breast Cancer Symposium (SABCS), held December 10-13 in San Antonio, Texas. This international symposium is directed primarily towards academic and private physicians and researchers involved in breast cancer in medical, surgical, gynecologic, and radiation oncology, as well as patient advocates and other appropriate health care professionals. An anticipated 10,000 attendees from more than 100 countries are expected this year. SABCS is designed to provide state-of-the-art information on the experimental biology, etiology, prevention, diagnosis, and therapy of breast cancer and premalignant breast disease, to an international audience of academic and private physicians and researchers.  

Jennifer Ligibel, MD Discusses Weigh Loss Intervention Video

Jennifer Ligibel, MD Discusses Weigh Loss Intervention

Dana-Farber's Jennifer Ligibel, MD reviews a telephone-based weight loss intervention that led to significant improvements in metabolic and inflammatory biomarkers associated with cancer recurrence according to new data. 
Jennifer Ligibel, MD

Jennifer Ligibel, MD

Medical Oncology
Antonio Giordano, MD, PhD Discusses Novel CDK4-Selective Inhibitor Video

Antonio Giordano, MD, PhD Discusses Novel CDK4-Selective Inhibitor

Dana-Farber's Antonia Giordano, MD, PhD shares new data on a novel CDK4-selective inhibitor in como with letrozole as 1st line treatment in HR+/HER2 Metastatic Breast Cancer.
Antonio Giordano, MD Giordano, PhD

Antonio Giordano, MD Giordano, PhD

Assistant Professor of Medicine, Harvard Medical School
Ada Waks, MD Presents Results of the MARGOT Study Video

Ada Waks, MD Presents Results of the MARGOT Study

Dana-Farber's Ada Waks, MD presented results of MARGOT, a phase 2 trial comparing margetuximab plus chemo or trastuzumab plus chemo in patients with early stage HER2+ breast cancer.
Adrienne Waks, MD

Adrienne Waks, MD

Associate Director, Clinical Research
Judy Garber, MD, MPH Presents Updated Results of the OlympiA Study Video

Judy Garber, MD, MPH Presents Updated Results of the OlympiA Study

Dana-Farber’s Judy Garber, MD, MPH shared updated results from the phase 3 OlympiA study. The new analysis provides further support for olaparib’s benefits in patients with high-risk, HER2-negative breast cancer with germline mutations in BRCA1 or BRCA2.
Judy Garber, MD

Judy Garber, MD

Medical Oncology
Ann Partridge, MD, MPH Presents PROs from the COMET Study Video

Ann Partridge, MD, MPH Presents PROs from the COMET Study

Patients with low-risk DCIS who underwent active monitoring had comparable physical, emotional, and psychological outcomes to patients who received standard treatment, according to results from the phase 3 COMET trial data presented by ...
Ann Partridge, MD

Ann Partridge, MD

Medical Oncology

For live Symposium coverage and more, follow Dana-Farber and Dana-Farber News on X (formerly Twitter)

Presentation and Poster Schedules

 

Resources

 

News Releases